{"transactions":[{"id":914166,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T17:41:35.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":33.2,"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-26-012196","document":"tm265471-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465926012196/tm265471-11_4seq1.xml","form_type":"4"}},{"id":914165,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T17:41:35.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":48.3,"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001104659-26-012196","document":"tm265471-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465926012196/tm265471-11_4seq1.xml","form_type":"4"}},{"id":914164,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T17:41:35.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1920,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":61.9,"underlying":"Common Stock","underlying_shares":1920},"source":{"system":"sec-edgar","filing":"0001104659-26-012196","document":"tm265471-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465926012196/tm265471-11_4seq1.xml","form_type":"4"}},{"id":914163,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T17:41:35.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":265.9,"underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001104659-26-012196","document":"tm265471-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465926012196/tm265471-11_4seq1.xml","form_type":"4"}},{"id":914162,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T17:41:35.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":190,"underlying":"Common Stock","underlying_shares":5200},"source":{"system":"sec-edgar","filing":"0001104659-26-012196","document":"tm265471-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465926012196/tm265471-11_4seq1.xml","form_type":"4"}},{"id":914161,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T17:41:35.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4246,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":45.924,"underlying":"Common Stock","underlying_shares":4246},"source":{"system":"sec-edgar","filing":"0001104659-26-012196","document":"tm265471-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465926012196/tm265471-11_4seq1.xml","form_type":"4"}},{"id":914160,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T17:41:35.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.874,"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-26-012196","document":"tm265471-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465926012196/tm265471-11_4seq1.xml","form_type":"4"}},{"id":914159,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-09T17:41:35.000Z","date":"2026-02-09","kind":"other","planned":false,"acquired":false,"shares":53475,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-012196","document":"tm265471-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465926012196/tm265471-11_4seq1.xml","form_type":"4"}},{"id":950422,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T20:25:57.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20400,"derivative":{"exercise_price":35.42,"exercise_date":"2027-01-02","expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001193125-26-003110","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312526003110/ownership.xml","form_type":"4"}},{"id":950421,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:25:57.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award."}],"balance_after":33150,"source":{"system":"sec-edgar","filing":"0001193125-26-003110","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312526003110/ownership.xml","form_type":"4"}},{"id":1012484,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-28T19:49:42.000Z","date":"2025-10-27","kind":"exercise","planned":false,"acquired":false,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":4.88,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001193125-25-254300","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312525254300/ownership.xml","form_type":"4"}},{"id":1012483,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-28T19:49:42.000Z","date":"2025-10-27","kind":"exercise","planned":false,"acquired":false,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001193125-25-254300","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312525254300/ownership.xml","form_type":"4"}},{"id":1012482,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-28T19:49:42.000Z","date":"2025-10-27","kind":"exercise","planned":false,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":4.48,"exercise_date":"2019-01-02","expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001193125-25-254300","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312525254300/ownership.xml","form_type":"4"}},{"id":1012481,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T19:49:42.000Z","date":"2025-10-27","kind":"sale","planned":false,"acquired":false,"shares":60000,"price":35.5713,"value":2134278.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.02 to $35.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001193125-25-254300","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312525254300/ownership.xml","form_type":"4"}},{"id":1012480,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T19:49:42.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":4.88,"value":107360.0,"ownership":{"direct":true},"balance_after":90000,"source":{"system":"sec-edgar","filing":"0001193125-25-254300","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312525254300/ownership.xml","form_type":"4"}},{"id":1012479,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T19:49:42.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":5.8,"value":127600.0,"ownership":{"direct":true},"balance_after":68000,"source":{"system":"sec-edgar","filing":"0001193125-25-254300","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312525254300/ownership.xml","form_type":"4"}},{"id":1012478,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T19:49:42.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":4.48,"value":71680.0,"ownership":{"direct":true},"balance_after":46000,"source":{"system":"sec-edgar","filing":"0001193125-25-254300","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312525254300/ownership.xml","form_type":"4"}},{"id":1119291,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T16:05:16.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 4, 2025. The shares underlying the option will fully vest on the earlier of: June 4, 2026 and the date of Generation Bio's 2026 annual meeting of stockholders."}],"balance_after":30000,"derivative":{"exercise_price":0.3874,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-015960","document":"form4-06062025_040611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000141588925015960/form4-06062025_040611.xml","form_type":"4"}},{"id":1309869,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-06T20:13:07.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":18800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18800,"derivative":{"exercise_price":41.12,"exercise_date":"2026-01-02","expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":18800},"source":{"system":"sec-edgar","filing":"0000950170-25-002482","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000095017025002482/ownership.xml","form_type":"4"}},{"id":1484574,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T16:05:26.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2024. The shares underlying the option will fully vest on the earlier of: June 6, 2025 and the date of Generation Bio's 2025 annual meeting of stockholders."}],"balance_after":60000,"derivative":{"exercise_price":3.32,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-24-016185","document":"form4-06102024_040617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000141588924016185/form4-06102024_040617.xml","form_type":"4"}},{"id":1671884,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T17:25:15.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares, nominal value GBP 0.10 per share (the \"Ordinary Shares\") may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents ten Ordinary Shares."}],"balance_after":0,"derivative":{"exercise_price":0.495,"expiration_date":"2033-06-13","underlying":"Ordinary Shares","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0000950170-24-007074","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000095017024007074/ownership.xml","form_type":"4"}},{"id":1671883,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T17:25:15.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares, nominal value GBP 0.10 per share (the \"Ordinary Shares\") may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents ten Ordinary Shares."}],"balance_after":0,"derivative":{"exercise_price":0.475,"expiration_date":"2032-06-06","underlying":"Ordinary Shares","underlying_shares":46000},"source":{"system":"sec-edgar","filing":"0000950170-24-007074","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000095017024007074/ownership.xml","form_type":"4"}},{"id":1671882,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-01-24T17:25:15.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12294,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares, nominal value GBP 0.10 per share (the \"Ordinary Shares\") may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents ten Ordinary Shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-007074","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000095017024007074/ownership.xml","form_type":"4"}},{"id":1687181,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-04T21:27:27.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":32000,"derivative":{"exercise_price":18.28,"exercise_date":"2025-01-02","expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001209191-24-000924","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919124000924/doc4.xml","form_type":"4"}},{"id":1721236,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-05T16:30:27.000Z","date":"2023-12-04","kind":"purchase","planned":false,"acquired":true,"shares":150000,"price":1.5,"value":225000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.34 to $1.55, inclusive."}],"balance_after":534757,"source":{"system":"sec-edgar","filing":"0001415889-23-015864","document":"form4-12052023_041219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000141588923015864/form4-12052023_041219.xml","form_type":"4"}},{"id":1721235,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-05T16:30:27.000Z","date":"2023-12-01","kind":"purchase","planned":false,"acquired":true,"shares":192960,"price":1.31,"value":252777.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.13 to $1.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4."}],"balance_after":384757,"source":{"system":"sec-edgar","filing":"0001415889-23-015864","document":"form4-12052023_041219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000141588923015864/form4-12052023_041219.xml","form_type":"4"}},{"id":1851623,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T16:30:09.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to this option vest upon the earlier to occur of June 14, 2024 or the date of the 2024 Annual General Meeting of the Company."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares."}],"balance_after":105000,"derivative":{"exercise_price":0.495,"expiration_date":"2033-06-13","underlying":"Ordinary Shares","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001209191-23-037904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919123037904/doc4.xml","form_type":"4"}},{"id":1858451,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T16:15:24.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 8, 2023. The shares underlying the option will fully vest on the earlier of: June 8, 2024 and the date of Generation Bio's 2024 annual meeting of stockholders."}],"balance_after":25000,"derivative":{"exercise_price":4.83,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-23-009611","document":"form4-06122023_040618.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000141588923009611/form4-06122023_040618.xml","form_type":"4"}},{"id":1886565,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-18T18:31:30.000Z","date":"2023-05-16","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":0,"derivative":{"exercise_price":1.08,"exercise_date":"2018-07-01","expiration_date":"2027-07-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-030796","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919123030796/doc4.xml","form_type":"4"}},{"id":1886564,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-05-18T18:31:30.000Z","date":"2023-05-16","kind":"sale","planned":false,"acquired":false,"shares":40000,"price":25,"value":1000000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-23-030796","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919123030796/doc4.xml","form_type":"4"}},{"id":1886563,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2023-05-18T18:31:30.000Z","date":"2023-05-16","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":1.08,"value":43200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":70000,"source":{"system":"sec-edgar","filing":"0001209191-23-030796","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919123030796/doc4.xml","form_type":"4"}},{"id":2066196,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T18:12:46.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":8.52,"exercise_date":"2024-01-03","expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-23-001313","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919123001313/doc4.xml","form_type":"4"}},{"id":2153905,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-20T16:16:45.000Z","date":"2022-09-19","kind":"purchase","acquired":true,"shares":15750,"price":5.26,"value":82845.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.14 to $5.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":191797,"source":{"system":"sec-edgar","filing":"0001415889-22-009796","document":"form4-09202022_010937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000141588922009796/form4-09202022_010937.xml","form_type":"4"}},{"id":2155344,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-19T17:21:11.000Z","date":"2022-09-16","kind":"purchase","acquired":true,"shares":33481,"price":5.48,"value":183475.88,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.29 to $5.73, inclusive."}],"balance_after":176047,"source":{"system":"sec-edgar","filing":"0001415889-22-009776","document":"form4-09192022_020903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000141588922009776/form4-09192022_020903.xml","form_type":"4"}},{"id":2155343,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-19T17:21:11.000Z","date":"2022-09-15","kind":"purchase","acquired":true,"shares":17147,"price":5.41,"value":92765.27,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (2) of this Form 4."}],"balance_after":142566,"source":{"system":"sec-edgar","filing":"0001415889-22-009776","document":"form4-09192022_020903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000141588922009776/form4-09192022_020903.xml","form_type":"4"}},{"id":2158210,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T16:07:16.000Z","date":"2022-09-14","kind":"purchase","acquired":true,"shares":5600,"price":5.295,"value":29652.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.10 to $5.40, inclusive."}],"balance_after":125419,"source":{"system":"sec-edgar","filing":"0001415889-22-009671","document":"form4-09152022_010903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000141588922009671/form4-09152022_010903.xml","form_type":"4"}},{"id":2158209,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T16:07:16.000Z","date":"2022-09-13","kind":"purchase","acquired":true,"shares":18784,"price":5.204,"value":97751.936,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.08 to $5.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) of this Form 4."}],"balance_after":119819,"source":{"system":"sec-edgar","filing":"0001415889-22-009671","document":"form4-09152022_010903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000141588922009671/form4-09152022_010903.xml","form_type":"4"}},{"id":2195357,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-08-03T21:48:50.000Z","date":"2022-08-01","kind":"sale","acquired":false,"shares":8496,"price":0.175,"value":1486.8,"ownership":{"direct":true},"balance_after":15277,"source":{"system":"sec-edgar","filing":"0001104659-22-085790","document":"tm2222534-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465922085790/tm2222534-5_4seq1.xml","form_type":"4"}},{"id":2233795,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T16:05:38.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":19200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2022. The shares underlying the option will fully vest on the earlier of: June 9, 2023 and the date of Generation Bio's 2023 annual meeting of stockholders."}],"balance_after":19200,"derivative":{"exercise_price":6.19,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":19200},"source":{"system":"sec-edgar","filing":"0001415889-22-006477","document":"form4-06132022_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000141588922006477/form4-06132022_040612.xml","form_type":"4"}},{"id":2238796,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-08T16:05:56.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to this option vest upon the earlier to occur of June 7, 2023 or the date of the 2023 Annual General Meeting of the Company."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":46000,"derivative":{"exercise_price":0.4747,"expiration_date":"2032-06-06","underlying":"Ordinary Shares","underlying_shares":46000},"source":{"system":"sec-edgar","filing":"0001209191-22-035007","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919122035007/doc4.xml","form_type":"4"}},{"id":2442991,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-05T19:11:14.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":4.88,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-22-001983","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919122001983/doc4.xml","form_type":"4"}},{"id":2614392,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-08-04T21:05:35.000Z","date":"2021-08-02","kind":"sale","acquired":false,"shares":777,"price":1.2,"value":932.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.20 to $1.205, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":23773,"source":{"system":"sec-edgar","filing":"0001104659-21-100288","document":"tm2123911-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465921100288/tm2123911-5_4seq1.xml","form_type":"4"}},{"id":2621049,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2021-07-30T20:21:10.000Z","date":"2021-07-28","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"The option was granted on July 28, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One hundred percent (100%) of the option will vest on July 31, 2022, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc."}],"balance_after":35000,"derivative":{"exercise_price":1.08,"expiration_date":"2031-07-28","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-21-098427","document":"tm2123737-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465921098427/tm2123737-6_4seq1.xml","form_type":"4"}},{"id":2621048,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-07-30T20:21:10.000Z","date":"2021-07-28","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of ordinary shares reported on this Form 4 reflects a 1-for-10 reverse stock split effected on December 3, 2020."}],"balance_after":24550,"source":{"system":"sec-edgar","filing":"0001104659-21-098427","document":"tm2123737-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465921098427/tm2123737-6_4seq1.xml","form_type":"4"}},{"id":2663124,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T17:02:09.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to this option vest upon the earlier to occur of June 16, 2022 or the date of the 2022 Annual General Meeting of the Company."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":40000,"derivative":{"exercise_price":4.79,"expiration_date":"2031-06-15","underlying":"Ordinary Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-041507","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919121041507/doc4.xml","form_type":"4"}},{"id":2671439,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-11T16:09:50.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2021. The shares underlying the option will fully vest on the earlier of: June 9, 2022 and the date of Generation Bio's 2022 annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":26.59,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-21-002951","document":"form4-06112021_010625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000141588921002951/form4-06112021_010625.xml","form_type":"4"}},{"id":2680563,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T16:16:55.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022."}],"balance_after":4500,"derivative":{"exercise_price":87.13,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-21-006417","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911021006417/edgar.xml","form_type":"4"}},{"id":2680562,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T16:16:55.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":5812,"source":{"system":"sec-edgar","filing":"0001179110-21-006417","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911021006417/edgar.xml","form_type":"4"}},{"id":2907997,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-13T16:04:36.000Z","date":"2021-01-11","kind":"purchase","acquired":true,"shares":20408,"price":24.5,"value":499996.0,"ownership":{"direct":true},"balance_after":101035,"source":{"system":"sec-edgar","filing":"0001415889-21-000310","document":"form4-01132021_010126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000141588921000310/form4-01132021_010126.xml","form_type":"4"}},{"id":2914822,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-06T16:42:55.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":5.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-21-002140","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919121002140/doc4.xml","form_type":"4"}},{"id":2937452,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-18T16:09:26.000Z","date":"2020-12-17","kind":"exercise","acquired":false,"shares":10909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 23, 2016. This option is fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":19.53,"expiration_date":"2026-06-23","underlying":"Common Stock","underlying_shares":10909},"source":{"system":"sec-edgar","filing":"0001179110-20-012096","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020012096/edgar.xml","form_type":"4"}},{"id":2937451,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-18T16:09:26.000Z","date":"2020-12-17","kind":"sale","acquired":false,"shares":10909,"price":117.82,"value":1285298.38,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.31 to $118.23 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3562,"source":{"system":"sec-edgar","filing":"0001179110-20-012096","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020012096/edgar.xml","form_type":"4"}},{"id":2937450,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-18T16:09:26.000Z","date":"2020-12-17","kind":"exercise","acquired":true,"shares":10909,"price":19.53,"value":213052.77,"ownership":{"direct":true},"balance_after":14471,"source":{"system":"sec-edgar","filing":"0001179110-20-012096","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020012096/edgar.xml","form_type":"4"}},{"id":2992374,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-04T17:18:37.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":5522,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on March 22, 2015. This option is fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":9.46,"expiration_date":"2025-03-22","underlying":"Common Stock","underlying_shares":5522},"source":{"system":"sec-edgar","filing":"0001179110-20-010821","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020010821/edgar.xml","form_type":"4"}},{"id":2992373,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-04T17:18:37.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":4478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on March 22, 2015. This option is fully vested as of the date hereof."}],"balance_after":5522,"derivative":{"exercise_price":9.46,"expiration_date":"2025-03-22","underlying":"Common Stock","underlying_shares":4478},"source":{"system":"sec-edgar","filing":"0001179110-20-010821","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020010821/edgar.xml","form_type":"4"}},{"id":2992372,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T17:18:37.000Z","date":"2020-11-03","kind":"sale","acquired":false,"shares":694,"price":95.97,"value":66603.18,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.97 to $95.99 per share."}],"balance_after":3562,"source":{"system":"sec-edgar","filing":"0001179110-20-010821","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020010821/edgar.xml","form_type":"4"}},{"id":2992371,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T17:18:37.000Z","date":"2020-11-03","kind":"sale","acquired":false,"shares":4728,"price":99.1,"value":468544.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.00 to $99.68 per share."}],"balance_after":4256,"source":{"system":"sec-edgar","filing":"0001179110-20-010821","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020010821/edgar.xml","form_type":"4"}},{"id":2992370,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T17:18:37.000Z","date":"2020-11-03","kind":"sale","acquired":false,"shares":100,"price":100.48,"value":10048.0,"ownership":{"direct":true},"balance_after":8984,"source":{"system":"sec-edgar","filing":"0001179110-20-010821","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020010821/edgar.xml","form_type":"4"}},{"id":2992369,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T17:18:37.000Z","date":"2020-11-03","kind":"exercise","acquired":true,"shares":5522,"price":9.46,"value":52238.12,"ownership":{"direct":true},"balance_after":9084,"source":{"system":"sec-edgar","filing":"0001179110-20-010821","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020010821/edgar.xml","form_type":"4"}},{"id":2992368,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T17:18:37.000Z","date":"2020-11-02","kind":"sale","acquired":false,"shares":4478,"price":99.11,"value":443814.58,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.00 to $99.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (3) of this Form 4."}],"balance_after":3562,"source":{"system":"sec-edgar","filing":"0001179110-20-010821","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020010821/edgar.xml","form_type":"4"}},{"id":2992367,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T17:18:37.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":4478,"price":9.46,"value":42361.88,"ownership":{"direct":true},"balance_after":8040,"source":{"system":"sec-edgar","filing":"0001179110-20-010821","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020010821/edgar.xml","form_type":"4"}},{"id":3072333,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-07-31T16:55:20.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"The option was granted on July 29, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One hundred percent (100%) of the option will vest on July 31, 2021, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc."}],"balance_after":35000,"derivative":{"exercise_price":0.79,"expiration_date":"2030-07-28","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-20-089141","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465920089141/a4.xml","form_type":"4"}},{"id":3072332,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-07-31T16:55:20.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units."}],"balance_after":70500,"source":{"system":"sec-edgar","filing":"0001104659-20-089141","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465920089141/a4.xml","form_type":"4"}},{"id":3098316,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-26T16:10:31.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021."}],"balance_after":4500,"derivative":{"exercise_price":76.24,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-20-007793","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020007793/edgar.xml","form_type":"4"}},{"id":3098315,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-26T16:10:31.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":3562,"source":{"system":"sec-edgar","filing":"0001179110-20-007793","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020007793/edgar.xml","form_type":"4"}},{"id":3101669,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-23T16:15:52.000Z","date":"2020-06-19","kind":"exercise","acquired":false,"shares":1312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1312},"source":{"system":"sec-edgar","filing":"0001179110-20-007719","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020007719/edgar.xml","form_type":"4"}},{"id":3101668,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T16:15:52.000Z","date":"2020-06-19","kind":"exercise","acquired":true,"shares":1312,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1312,"source":{"system":"sec-edgar","filing":"0001179110-20-007719","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911020007719/edgar.xml","form_type":"4"}},{"id":3104036,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T16:18:00.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to this option vest upon the earlier to occur of June 17, 2021 or the date of the 2021 Annual General Meeting of the Company."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":35000,"derivative":{"exercise_price":7.81,"expiration_date":"2030-06-16","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-20-037918","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919120037918/doc4.xml","form_type":"4"}},{"id":3105145,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-06-18T17:30:16.000Z","date":"2020-06-16","kind":"exercise","acquired":false,"shares":89423,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50627},"source":{"system":"sec-edgar","filing":"0000899243-20-017105","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000089924320017105/doc4.xml","form_type":"4"}},{"id":3105144,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-18T17:30:16.000Z","date":"2020-06-16","kind":"purchase","acquired":true,"shares":30000,"price":19,"value":570000.0,"ownership":{"direct":true},"balance_after":80627,"source":{"system":"sec-edgar","filing":"0000899243-20-017105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000089924320017105/doc4.xml","form_type":"4"}},{"id":3105143,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-18T17:30:16.000Z","date":"2020-06-16","kind":"exercise","acquired":true,"shares":50627,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":50627,"source":{"system":"sec-edgar","filing":"0000899243-20-017105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000089924320017105/doc4.xml","form_type":"4"}},{"id":3110166,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-15T17:24:42.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on June 11, 2021 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":52000,"derivative":{"exercise_price":19,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0000899243-20-016554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000089924320016554/doc4.xml","form_type":"4"}},{"id":3321891,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-03T19:55:36.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":7.95,"exercise_date":"2021-01-02","expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-20-001419","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919120001419/doc4.xml","form_type":"4"}},{"id":3450561,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2019-08-01T16:19:19.000Z","date":"2019-07-31","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $2.38 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on July 31, 2019. One hundred percent (100%) of the option will vest on July 31, 2020, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc."}],"balance_after":35000,"derivative":{"expiration_date":"2029-07-31","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-19-043345","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465919043345/a4.xml","form_type":"4"}},{"id":3479842,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-24T20:08:27.000Z","date":"2019-06-20","kind":"exercise","acquired":false,"shares":11818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on March 22, 2015. This option vested with respect to 1/36th of the shares underlying the option on April 16, 2015 and vested as to an additional 1/36th of the shares underlying the option each month thereafter."}],"balance_after":10000,"derivative":{"exercise_price":9.46,"expiration_date":"2025-03-22","underlying":"Common Stock","underlying_shares":11818},"source":{"system":"sec-edgar","filing":"0001179110-19-008066","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911019008066/edgar.xml","form_type":"4"}},{"id":3479841,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-24T20:08:27.000Z","date":"2019-06-20","kind":"sale","acquired":false,"shares":9271,"price":94.83,"value":879168.93,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.63 to $94.89 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-19-008066","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911019008066/edgar.xml","form_type":"4"}},{"id":3479840,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-24T20:08:27.000Z","date":"2019-06-20","kind":"sale","acquired":false,"shares":1600,"price":96.08,"value":153728.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.00 to $96.25 per share."}],"balance_after":9271,"source":{"system":"sec-edgar","filing":"0001179110-19-008066","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911019008066/edgar.xml","form_type":"4"}},{"id":3479839,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-24T20:08:27.000Z","date":"2019-06-20","kind":"sale","acquired":false,"shares":947,"price":96.69,"value":91565.43,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.29 to $97.25 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (3) of this Form 4."}],"balance_after":10871,"source":{"system":"sec-edgar","filing":"0001179110-19-008066","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911019008066/edgar.xml","form_type":"4"}},{"id":3479838,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-24T20:08:27.000Z","date":"2019-06-20","kind":"exercise","acquired":true,"shares":11818,"price":9.46,"value":111798.28,"ownership":{"direct":true},"balance_after":11818,"source":{"system":"sec-edgar","filing":"0001179110-19-008066","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911019008066/edgar.xml","form_type":"4"}},{"id":3482244,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-20T16:39:39.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":1312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020."}],"balance_after":1312,"derivative":{"underlying":"Common Stock","underlying_shares":1312},"source":{"system":"sec-edgar","filing":"0001179110-19-007986","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911019007986/edgar.xml","form_type":"4"}},{"id":3482243,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-20T16:39:39.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":4875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020."}],"balance_after":4875,"derivative":{"exercise_price":96.77,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":4875},"source":{"system":"sec-edgar","filing":"0001179110-19-007986","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911019007986/edgar.xml","form_type":"4"}},{"id":3707648,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-03T20:20:41.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":8.32,"exercise_date":"2020-01-02","expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-19-001558","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919119001558/doc4.xml","form_type":"4"}},{"id":3717402,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-12-27T16:05:59.000Z","date":"2018-12-24","kind":"purchase","acquired":true,"shares":53000,"price":1.31,"value":69430.0,"ownership":{"direct":true},"balance_after":53000,"source":{"system":"sec-edgar","filing":"0001104659-18-074905","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465918074905/a4.xml","form_type":"4"}},{"id":3854742,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2018-08-02T17:53:07.000Z","date":"2018-08-01","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $2.53 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award was granted on August 1, 2018. The option award will vest in full on August 1, 2019."}],"balance_after":10000,"derivative":{"expiration_date":"2028-08-01","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-18-049252","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465918049252/a4.xml","form_type":"4"}},{"id":3883847,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-25T16:56:51.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2019."}],"balance_after":51136,"derivative":{"exercise_price":69.79,"expiration_date":"2028-06-21","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001179110-18-009001","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911018009001/edgar.xml","form_type":"4"}},{"id":3912084,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2018-05-31T19:02:06.000Z","date":"2018-05-29","kind":"purchase","acquired":true,"shares":30000,"price":5.16,"value":154800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.06 to $5.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-18-034490","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919118034490/doc4.xml","form_type":"4"}},{"id":3945336,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2018-05-04T16:06:57.000Z","date":"2018-05-02","kind":"grant","acquired":true,"shares":29000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $4.91 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on May 2, 2018. Vesting began on May 2, 2018 and ends on May 2, 2019. One hundred percent (100%) of the option will vest on May 2, 2019."}],"balance_after":29000,"derivative":{"expiration_date":"2028-05-02","underlying":"Ordinary Shares","underlying_shares":29000},"source":{"system":"sec-edgar","filing":"0001104659-18-030636","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465918030636/a4.xml","form_type":"4"}},{"id":4110661,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-03T16:17:01.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":4.48,"exercise_date":"2019-01-02","expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-18-000848","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919118000848/doc4.xml","form_type":"4"}},{"id":4205413,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-09-19T21:33:06.000Z","date":"2017-09-15","kind":"grant","acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $6.86 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on September 15, 2017. Vesting began on September 15, 2017 and ends on September 15, 2018. One hundred percent (100%) of the option will vest on September 15, 2018."}],"balance_after":10100,"derivative":{"expiration_date":"2027-09-15","underlying":"Ordinary Shares","underlying_shares":10100},"source":{"system":"sec-edgar","filing":"0001104659-17-057957","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465917057957/a4.xml","form_type":"4"}},{"id":4263466,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-07-05T21:34:54.000Z","date":"2017-07-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":40000,"derivative":{"exercise_price":1.08,"exercise_date":"2018-07-01","expiration_date":"2027-07-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-17-043855","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000120919117043855/doc4.xml","form_type":"4"}},{"id":4271546,"issuer":{"id":174291,"kind":"organization","name":"Nabriva Therapeutics Legacy plc","symbol":"NBRV"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-06-27T21:56:21.000Z","date":"2017-06-23","kind":"other","acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is 6.634 Euro."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG.  The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017."}],"balance_after":10100,"derivative":{"expiration_date":"2026-08-25","underlying":"Ordinary Shares","underlying_shares":10100},"source":{"system":"sec-edgar","filing":"0001104659-17-041906","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465917041906/a4.xml","form_type":"4"}},{"id":4271545,"issuer":{"id":174291,"kind":"organization","name":"Nabriva Therapeutics Legacy plc","symbol":"NBRV"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-06-27T21:56:21.000Z","date":"2017-06-23","kind":"other","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is 6.618 Euro."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG.  The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016."}],"balance_after":16000,"derivative":{"expiration_date":"2025-07-05","underlying":"Ordinary Shares","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-17-041906","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000110465917041906/a4.xml","form_type":"4"}},{"id":4273247,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-23T16:21:19.000Z","date":"2017-06-21","kind":"grant","acquired":true,"shares":10909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2018."}],"balance_after":43636,"derivative":{"exercise_price":46.02,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":10909},"source":{"system":"sec-edgar","filing":"0001179110-17-009516","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000117911017009516/edgar.xml","form_type":"4"}},{"id":4574982,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-25T16:34:31.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":10000,"price":11.38,"value":113800.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above."}],"balance_after":0,"derivative":{"exercise_price":9.62,"expiration_date":"2026-05-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-16-151949","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151949/a4.xml","form_type":"4"}},{"id":4574981,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-25T16:34:31.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":10000,"price":8.57,"value":85700.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above."}],"balance_after":0,"derivative":{"exercise_price":12.43,"expiration_date":"2025-05-27","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-16-151949","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151949/a4.xml","form_type":"4"}},{"id":4574980,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-25T16:34:31.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":17000,"price":13,"value":221000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above."}],"balance_after":0,"derivative":{"exercise_price":8,"expiration_date":"2024-09-23","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-16-151949","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151949/a4.xml","form_type":"4"}}]}